Oncomatryx LAUREANO SIMON, Oncomatryx CEO, declares war on tumor microenvironment. «We envision a new era where cancer in general and invasive tumors in particular will be beaten with orchestrated combinations of precision drugs that target the epitelial tumor cells, to block tumor growth and drugs that target the tumor microenvironment, to block tumor invasion, angiogenesis, metastasis, immunosupression and drug resistance. … Leer más
Oncomatryx estará presenté en el Congreso de la Sociedad Europea de Ondocología Médica en Munich ESMO 2018 Congress Munich, Germany – 19 Oct – 23 Oct 2018 La Dra. Myriam Fabre (Oncomatryx R&D Director) presenta el poster: OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments Myriam … Leer más
ESMO 2018 Congress Munich, Germany – 19 Oct – 23 Oct 2018 Myriam Fabre, PhD. (Oncomatryx R&D Director) presents the poster: OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments Myriam Fabre1,6, Cristina Ferrer1, Saioa Domínguez-Hormaetxe1, Roland Kontermann2, Klaus Pfizenmaier2, Oliver Seifert2, Pedro P. López-Casas3, Muhammad Abbas4, Wolfgang Richter4, … Leer más
Oncomatryx asistirá a la BIO EUROPE SPRING 2018, cita imprescindible en Europa BIO EUROPE SPRING 2018 Marzo 12-14, 2018 Amsterdam, Holanda https://ebdgroup.knect365.com/bioeurope- Si también va a asistir y quiere que nos veamos puede escribirnos un email mediante el formulario adjunto [contact-form-7 id=»2869″ title=»Conference Appointment»]
Oncomatryx will attend BIO EUROPE SPRING 2018, the essential appointment in biotechnology BIO EUROPE SPRING 2018 March 12-14, 2018 Amsterdam, The Netherlands https://ebdgroup.knect365.com/bioeurope- If you are also attending this event and you would like to meet us please fill this form to arrange an appointment. [contact-form-7 id=»2869″ title=»Conference Appointment»]
Oncomatryx will attend BIO 2017, the Global Event for Biotechnology. [vc_row][vc_column width=»1/3″][vc_column_text][/vc_column_text][/vc_column][vc_column width=»2/3″][vc_column_text] BIO 2017 June 19-22, 2017 San Diego Convention Center. San Diego, CA. USA. http://convention.bio.org/2017/ [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_separator border_width=»2″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] If you are also attending any of these events and you would like to meet us please fill this form to arrange an appointment. [/vc_column_text][vc_column_text] [/vc_column_text][contact-form-7 … Leer más
Oncomatryx will attend BIO 2017, the Global Event for Biotechnology. [vc_row][vc_column width=»1/3″][vc_column_text][/vc_column_text][/vc_column][vc_column width=»2/3″][vc_column_text] BIO 2017 June 19-22, 2017 San Diego Convention Center. San Diego, CA. USA. http://convention.bio.org/2017/ [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_separator border_width=»2″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] If you are also attending any of these events and you would like to meet us please fill this form to arrange an appointment. [/vc_column_text][vc_column_text] [/vc_column_text][contact-form-7 … Leer más
ENTURE SUMMIT WEST 2017 28 de Febrero – 1 de Marzo de 2017 Mountain View, CA USA David Raksin, our Business Development Director will be a Presenting role as a Top Innovator in the Life Sciences Track. http://www.youngstartup.com/west2017/overview.php 10TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM & EXHIBITION March 6 -7 2017 Zurich, Switzerland Our CEO, Laureano Simón … Leer más
ENTURE SUMMIT WEST 2017 February 28 – March 1 2017 Mountain View, CA USA David Raksin, our Business Development Director will be a Presenting role as a Top Innovator in the Life Sciences Track. http://www.youngstartup.com/west2017/overview.php 10TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM & EXHIBITION March 6 -7 2017 Zurich, Switzerland Our CEO, Laureano Simón will … Leer más
Antibody Drug Conjugates Against Tumor Stroma: The Beginning of The End? by Mirella Zulueta, Business Development Director at Oncomatryx The potential of a technology trigger Despite many research breakthroughs over the last few decades, conventional cancer treatment strategies still face many limitations. Antibody-drug conjugates (ADCs) belong to a fairly new class of targeted cell … Leer más
